242 related articles for article (PubMed ID: 36986491)
1. Current Trends in Neoantigen-Based Cancer Vaccines.
Ho SY; Chang CM; Liao HN; Chou WH; Guo CL; Yen Y; Nakamura Y; Chang WC
Pharmaceuticals (Basel); 2023 Mar; 16(3):. PubMed ID: 36986491
[TBL] [Abstract][Full Text] [Related]
2. Engineering neoantigen vaccines to improve cancer personalized immunotherapy.
Liu Z; Lv J; Dang Q; Liu L; Weng S; Wang L; Zhou Z; Kong Y; Li H; Han Y; Han X
Int J Biol Sci; 2022; 18(15):5607-5623. PubMed ID: 36263174
[TBL] [Abstract][Full Text] [Related]
3. Immune-based mutation classification enables neoantigen prioritization and immune feature discovery in cancer immunotherapy.
Bai P; Li Y; Zhou Q; Xia J; Wei PC; Deng H; Wu M; Chan SK; Kappler JW; Zhou Y; Tran E; Marrack P; Yin L
Oncoimmunology; 2021 Jan; 10(1):1868130. PubMed ID: 33537173
[TBL] [Abstract][Full Text] [Related]
4. Tumor neoantigens: from basic research to clinical applications.
Jiang T; Shi T; Zhang H; Hu J; Song Y; Wei J; Ren S; Zhou C
J Hematol Oncol; 2019 Sep; 12(1):93. PubMed ID: 31492199
[TBL] [Abstract][Full Text] [Related]
5. Induction of Neoantigen-Specific Cytotoxic T Cells and Construction of T-cell Receptor-Engineered T Cells for Ovarian Cancer.
Matsuda T; Leisegang M; Park JH; Ren L; Kato T; Ikeda Y; Harada M; Kiyotani K; Lengyel E; Fleming GF; Nakamura Y
Clin Cancer Res; 2018 Nov; 24(21):5357-5367. PubMed ID: 29720506
[No Abstract] [Full Text] [Related]
6. Neoantigen-reactive T cells exhibit effective anti-tumor activity against colorectal cancer.
Yu Y; Zhang J; Ni L; Zhu Y; Yu H; Teng Y; Lin L; Xue Z; Xue X; Shen X; Song H; Su X; Sun W; Cai Z
Hum Vaccin Immunother; 2022 Dec; 18(1):1-11. PubMed ID: 33689574
[TBL] [Abstract][Full Text] [Related]
7. Immunological ignorance is an enabling feature of the oligo-clonal T cell response to melanoma neoantigens.
Linette GP; Becker-Hapak M; Skidmore ZL; Baroja ML; Xu C; Hundal J; Spencer DH; Fu W; Cummins C; Robnett M; Kaabinejadian S; Hildebrand WH; Magrini V; Demeter R; Krupnick AS; Griffith OL; Griffith M; Mardis ER; Carreno BM
Proc Natl Acad Sci U S A; 2019 Nov; 116(47):23662-23670. PubMed ID: 31685621
[TBL] [Abstract][Full Text] [Related]
8. Identification of T Cell Receptors Targeting a Neoantigen Derived from Recurrently Mutated FGFR3.
Tate T; Matsumoto S; Nemoto K; Leisegang M; Nagayama S; Obama K; Nakamura Y; Kiyotani K
Cancers (Basel); 2023 Feb; 15(4):. PubMed ID: 36831375
[TBL] [Abstract][Full Text] [Related]
9. Neoantigens and NK Cells: "Trick or Treat" the Cancers?
Lv D; Khawar MB; Liang Z; Gao Y; Sun H
Front Immunol; 2022; 13():931862. PubMed ID: 35874694
[TBL] [Abstract][Full Text] [Related]
10. Beyond Sequencing: Prioritizing and Delivering Neoantigens for Cancer Vaccines.
Roesler AS; Anderson KS
Methods Mol Biol; 2022; 2410():649-670. PubMed ID: 34914074
[TBL] [Abstract][Full Text] [Related]
11. Neoantigens in precision cancer immunotherapy: from identification to clinical applications.
Zhang Q; Jia Q; Zhang J; Zhu B
Chin Med J (Engl); 2022 Jun; 135(11):1285-1298. PubMed ID: 35838545
[TBL] [Abstract][Full Text] [Related]
12. Driving neoantigen-based cancer vaccines for personalized immunotherapy into clinic: A burdensome journey to promising land.
Yu G; He X; Li X; Wu Y
Biomed Pharmacother; 2022 Sep; 153():113464. PubMed ID: 36076493
[TBL] [Abstract][Full Text] [Related]
13. A Synthetic DNA, Multi-Neoantigen Vaccine Drives Predominately MHC Class I CD8
Duperret EK; Perales-Puchalt A; Stoltz R; G H H; Mandloi N; Barlow J; Chaudhuri A; Sardesai NY; Weiner DB
Cancer Immunol Res; 2019 Feb; 7(2):174-182. PubMed ID: 30679156
[TBL] [Abstract][Full Text] [Related]
14. Neoantigen vaccine platforms in clinical development: understanding the future of personalized immunotherapy.
Supabphol S; Li L; Goedegebuure SP; Gillanders WE
Expert Opin Investig Drugs; 2021 May; 30(5):529-541. PubMed ID: 33641576
[TBL] [Abstract][Full Text] [Related]
15. Cancer Neoantigens: Challenges and Future Directions for Prediction, Prioritization, and Validation.
Borden ES; Buetow KH; Wilson MA; Hastings KT
Front Oncol; 2022; 12():836821. PubMed ID: 35311072
[TBL] [Abstract][Full Text] [Related]
16. Neoantigen Vaccine Delivery for Personalized Anticancer Immunotherapy.
Guo Y; Lei K; Tang L
Front Immunol; 2018; 9():1499. PubMed ID: 30013560
[TBL] [Abstract][Full Text] [Related]
17. Proteogenomic Platform for Identification of Tumor Specific Antigens.
Faktor J; Hernychová L; Vojtěšek B; Hupp T
Klin Onkol; 2018; 31(Suppl 2):102-107. PubMed ID: 31023032
[TBL] [Abstract][Full Text] [Related]
18. Personalized Neoantigen-Pulsed DC Vaccines: Advances in Clinical Applications.
Tang L; Zhang R; Zhang X; Yang L
Front Oncol; 2021; 11():701777. PubMed ID: 34381724
[TBL] [Abstract][Full Text] [Related]
19. Neoantigen identification strategies enable personalized immunotherapy in refractory solid tumors.
Chen F; Zou Z; Du J; Su S; Shao J; Meng F; Yang J; Xu Q; Ding N; Yang Y; Liu Q; Wang Q; Sun Z; Zhou S; Du S; Wei J; Liu B
J Clin Invest; 2019 May; 129(5):2056-2070. PubMed ID: 30835255
[TBL] [Abstract][Full Text] [Related]
20. Neoantigen vaccine: an emerging tumor immunotherapy.
Peng M; Mo Y; Wang Y; Wu P; Zhang Y; Xiong F; Guo C; Wu X; Li Y; Li X; Li G; Xiong W; Zeng Z
Mol Cancer; 2019 Aug; 18(1):128. PubMed ID: 31443694
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
